Metagenomi Therapeutics, Inc. (NASDAQ:MGX)
| Market Cap | $21.85M-61.7% |
| Revenue (ttm) | $7.09M-77.1% |
| Net Income | -$94.19M-6.1% |
| EPS | -$2.50-4.2% |
| Shares Out | 37.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,752.568 |
| Open | $0.62 |
| Previous Close | $0.61 |
| Day's Range | $0.57 - $0.62 |
| 52-Week Range | $0.57 - $1.87 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | $14.50(+2409.08%) |
| Earnings Date | Mar 4, 2027 |
About MGX
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Metagenomi Therapeutics, Inc. Stock Analysis — InsiderScore
Metagenomi Therapeutics, Inc. scored higher than 40% of companies evaluated by InsiderBuying, and ranked 46th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Metagenomi Therapeutics, Inc. bought $23.4K of stock across 2 purchases in the last 90 days, the largest of them $23.3K.
The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$MGX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MGX Revenue by Segment
| Facilities and overhead costs | $6.28M | 48.57% |
| Professional services and consulting | $3.20M | 24.76% |
| Ionis | $2.20M | 17.01% |
| Interest and other | $1.10M | 8.50% |
| Affini-T | $125.00K | 0.97% |
| Other | $25.00K | 0.19% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MGX
| VTIVanguard Morningstar Total Stock Market ETF | $455.89K |
| VXFVanguard Extended Market ETF | $246.15K |
| IWCiShares Micro-Cap ETF | $53.21K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $20.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MGX’s recent data — informational, not investment advice
What’s Behind the Score
News check: FDA clearance for lead program and Q3 results announcement drive bullish sentiment; conference presentation supports positive visibility.
Recent Insider Activity
Insider Score Trend Over Time
-3.9 since Sep 16Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.03% |
Weight is the stock’s share of each fund’s holdings.
